Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Barry Uretsky to Heart Failure

This is a "connection" page, showing publications Barry Uretsky has written about Heart Failure.

 
Connection Strength
  
 
 
3.439
  
  1. Uretsky BF, Vallurupalli S. Is the Digitalis Leaf Still Withering? J Am Coll Cardiol. 2019 08 06; 74(5):628-630.
    View in: PubMed
    Score: 0.455
  2. Rosanio S, Schwarz ER, Vitarelli A, Zarraga IG, Kunapuli S, Ware DL, Birnbaum Y, Tuero E, Uretsky BF. Sudden death prophylaxis in heart failure. Int J Cardiol. 2007 Jul 31; 119(3):291-6.
    View in: PubMed
    Score: 0.191
  3. Gupta R, Birnbaum Y, Uretsky BF. Calculation of creatinine clearance based on unadjusted body weight leads to errors in renal and heart failure patients. Circulation. 2004 Aug 17; 110(7):e70.
    View in: PubMed
    Score: 0.161
  4. Triska J, Uretsky BF, Pitt B, Birnbaum Y. Closing the Digitalis Divide: Back to the Basics of Randomized Controlled Trials. Cardiovasc Drugs Ther. 2023 08; 37(4):807-813.
    View in: PubMed
    Score: 0.133
  5. Lenihan DJ, Uretsky BF. Nonpharmacologic treatment of heart failure in the elderly. Clin Geriatr Med. 2000 Aug; 16(3):477-88.
    View in: PubMed
    Score: 0.122
  6. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryd?n L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999 Dec 07; 100(23):2312-8.
    View in: PubMed
    Score: 0.117
  7. Uretsky BF, Pina I, Quigg RJ, Brill JV, MacInerney EJ, Mintzer R, Armstrong PW. Beyond drug therapy: nonpharmacologic care of the patient with advanced heart failure. Am Heart J. 1998 Jun; 135(6 Pt 2 Su):S264-84.
    View in: PubMed
    Score: 0.105
  8. Uretsky BF, Sheahan RG. Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? J Am Coll Cardiol. 1997 Dec; 30(7):1589-97.
    View in: PubMed
    Score: 0.101
  9. MacGowan GA, Murali S, Loftus S, Uretsky BF. Comparison of metabolic, ventilatory, and neurohumoral responses during light forearm isometric exercise and isotonic exercise in congestive heart failure. Am J Cardiol. 1996 Feb 15; 77(5):391-6.
    View in: PubMed
    Score: 0.089
  10. Uretsky BF. Digoxin in the treatment of patients with chronic heart failure. Its place in therapy. Drugs Aging. 1995 Jul; 7(1):1-9.
    View in: PubMed
    Score: 0.086
  11. Ward RE, Gheorghiade M, Young JB, Uretsky B. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure. J Am Coll Cardiol. 1995 Jul; 26(1):93-101.
    View in: PubMed
    Score: 0.086
  12. Rosenbaum AM, Murali S, Uretsky BF. Intra-aortic balloon counterpulsation as a 'bridge' to cardiac transplantation. Effects in nonischemic and ischemic cardiomyopathy. Chest. 1994 Dec; 106(6):1683-8.
    View in: PubMed
    Score: 0.082
  13. Carell ES, Murali S, Schulman DS, Estrada-Quintero T, Uretsky BF. Maximal exercise tolerance in chronic congestive heart failure. Relationship to resting left ventricular function. Chest. 1994 Dec; 106(6):1746-52.
    View in: PubMed
    Score: 0.082
  14. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol. 1993 Oct; 22(4):955-62.
    View in: PubMed
    Score: 0.076
  15. Uretsky BF, Hua J. Combined intravenous pharmacotherapy in the treatment of patients with decompensated congestive heart failure. Am Heart J. 1991 Jun; 121(6 Pt 1):1879-86.
    View in: PubMed
    Score: 0.065
  16. Aleti S, Bansal D, Agrawal M, Uretsky BF, Sachdeva R. Effect of chronic angiotensin converting enzyme inhibitor therapy on myocardial injury in patients undergoing percutaneous coronary interventions. J Invasive Cardiol. 2011 Feb; 23(2):72-5.
    View in: PubMed
    Score: 0.063
  17. Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J, Murali S, Herrmann HC, Sandberg JA. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation. 1990 Sep; 82(3):774-80.
    View in: PubMed
    Score: 0.061
  18. Uretsky BF, Verbalis JG, Murali S, Betschart AR, Kolesar JA, Reddy PS. Control of atrial natriuretic peptide secretion in patients with severe congestive heart failure. J Clin Endocrinol Metab. 1990 Jul; 71(1):146-51.
    View in: PubMed
    Score: 0.061
  19. Uretsky BF, Shaver JA, Liang CS, Amin D, Shah PK, Levine TB, Walinsky P, LeJemtel T, Linnemaier T. Lisinopril for severe congestive heart failure. Am J Cardiol. 1989 Feb 21; 63(8):8D-11D.
    View in: PubMed
    Score: 0.055
  20. Uretsky BF, Shaver JA, Liang CS, Amin D, Shah PK, Levine TB, Walinsky P, LeJemtel T, Linnemeier T, Rush JE, et al. Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses. Am Heart J. 1988 Aug; 116(2 Pt 1):480-8.
    View in: PubMed
    Score: 0.053
  21. Uretsky BF. Diagnostic considerations in the adult patient with cardiomyopathy or congestive heart failure. Cardiovasc Clin. 1988; 19(1):35-56.
    View in: PubMed
    Score: 0.051
  22. Uretsky BF, Lawless CE, Verbalis JG, Valdes AM, Kolesar JA, Reddy PS. Combined therapy with dobutamine and amrinone in severe heart failure. Improved hemodynamics and increased activation of the renin-angiotensin system with combined intravenous therapy. Chest. 1987 Oct; 92(4):657-62.
    View in: PubMed
    Score: 0.050
  23. Rahko PS, Salerni R, Uretsky BF. Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. J Am Coll Cardiol. 1986 Aug; 8(2):436-40.
    View in: PubMed
    Score: 0.046
  24. Uretsky BF, Generalovich T, Verbalis JG, Valdes AM, Reddy PS. Comparative hemodynamic and hormonal response of enoximone and dobutamine in severe congestive heart failure. Am J Cardiol. 1986 Jul 01; 58(1):110-6.
    View in: PubMed
    Score: 0.046
  25. Islam J, Uretsky BF, Sierpina VS. Heart failure improvement with CoQ10, Hawthorn, and magnesium in a patient scheduled for cardiac resynchronization-defibrillator therapy: a case study. Explore (NY). 2006 Jul-Aug; 2(4):339-41.
    View in: PubMed
    Score: 0.046
  26. Uretsky BF. Is inotropic therapy appropriate for patients with chronic congestive heart failure? Or is the digitalis leaf withering? Postgrad Med J. 1986 Jun; 62(728):585-92.
    View in: PubMed
    Score: 0.046
  27. Rahko PS, Shaver JA, Salerni R, Uretsky BF. Noninvasive evaluation of systolic and diastolic function in severe congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1986 Jun 01; 57(15):1315-22.
    View in: PubMed
    Score: 0.046
  28. Rangasetty UC, Gheorghiade M, Uretsky BF, Orlandi C, Barbagelata A. Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure. Expert Opin Investig Drugs. 2006 May; 15(5):533-40.
    View in: PubMed
    Score: 0.045
  29. Uretsky BF, Valdes AM, Reddy PS. Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043. Circulation. 1986 Mar; 73(3 Pt 2):III219-29.
    View in: PubMed
    Score: 0.045
  30. Uretsky BF, Seecof RM, Reddy PS. The acute hemodynamic response to pirbuterol at rest and exercise in patients with heart failure with observations on long-term response. Can J Cardiol. 1986 Mar-Apr; 2(2):80-5.
    View in: PubMed
    Score: 0.045
  31. Rosanio S, Schwarz ER, Ahmad M, Jammula P, Vitarelli A, Uretsky BF, Birnbaum Y, Ware DL, Atar S, Saeed M. Benefits, unresolved questions, and technical issues of cardiac resynchronization therapy for heart failure. Am J Cardiol. 2005 Sep 01; 96(5):710-7.
    View in: PubMed
    Score: 0.043
  32. Uretsky BF, Generalovich T, Verbalis JG, Valdes AM, Reddy PS. MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response. J Am Coll Cardiol. 1985 Jun; 5(6):1414-21.
    View in: PubMed
    Score: 0.043
  33. Uretsky BF, Verbalis JG, Generalovich T, Valdes A, Reddy PS. Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure. Am J Physiol. 1985 Mar; 248(3 Pt 2):H396-402.
    View in: PubMed
    Score: 0.042
  34. Sanghi P, Uretsky BF, Schwarz ER. Vasopressin antagonism: a future treatment option in heart failure. Eur Heart J. 2005 Mar; 26(6):538-43.
    View in: PubMed
    Score: 0.042
  35. Uretsky BF, Generalovich T, Reddy PS, Salerni R, Valdes AM, Spangenberg RB, Lang JF, Okerholm RA. Acute hemodynamic effect of oral MDL 17,043 in severe congestive heart failure. Am J Cardiol. 1984 Aug 01; 54(3):357-62.
    View in: PubMed
    Score: 0.040
  36. Uretsky BF, Generalovich T, Reddy PS, Spangenberg RB, Follansbee WP. The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure. Circulation. 1983 Apr; 67(4):823-8.
    View in: PubMed
    Score: 0.037
  37. Poole-Wilson PA, Uretsky BF, Thygesen K, Cleland JG, Massie BM, Ryd?n L. Mode of death in heart failure: findings from the ATLAS trial. Heart. 2003 Jan; 89(1):42-8.
    View in: PubMed
    Score: 0.036
  38. Adams KF, Gheorghiade M, Uretsky BF, Patterson JH, Schwartz TA, Young JB. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol. 2002 Mar 20; 39(6):946-53.
    View in: PubMed
    Score: 0.034
  39. Cleland JG, Thygesen K, Uretsky BF, Armstrong P, Horowitz JD, Massie B, Packer M, Poole-Wilson PA, Ryd?n L. Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. Eur Heart J. 2001 Sep; 22(17):1601-12.
    View in: PubMed
    Score: 0.033
  40. Shah MR, Stinnett SS, McNulty SE, Gheorghiade M, Zannad F, Uretsky B, Adams KF, Califf RM, O'connor CM. Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRST. Am Heart J. 2001 Jun; 141(6):908-14.
    View in: PubMed
    Score: 0.032
  41. O'Connor CM, Gattis WA, Uretsky BF, Adams KF, McNulty SE, Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M, Califf RM. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999 Jul; 138(1 Pt 1):78-86.
    View in: PubMed
    Score: 0.028
  42. Young JB, Gheorghiade M, Uretsky BF, Patterson JH, Adams KF. Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Converting Enzyme. J Am Coll Cardiol. 1998 Sep; 32(3):686-92.
    View in: PubMed
    Score: 0.027
  43. Lo MW, Toh J, Emmert SE, Ritter MA, Furtek CI, Lu H, Colucci WS, Uretsky BF, Rucinska E. Pharmacokinetics of intravenous and oral losartan in patients with heart failure. J Clin Pharmacol. 1998 Jun; 38(6):525-32.
    View in: PubMed
    Score: 0.026
  44. Adams KF, Gheorghiade M, Uretsky BF, Young JB, Patterson JH, Tomasko L, Packer M. Clinical predictors of worsening heart failure during withdrawal from digoxin therapy. Am Heart J. 1998 Mar; 135(3):389-97.
    View in: PubMed
    Score: 0.026
  45. Adams KF, Gheorghiade M, Uretsky BF, Young JB, Ahmed S, Tomasko L, Packer M. Patients with mild heart failure worsen during withdrawal from digoxin therapy. J Am Coll Cardiol. 1997 Jul; 30(1):42-8.
    View in: PubMed
    Score: 0.025
  46. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE, Wheeler W, Soler-Soler J, Swedberg K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997 Jul; 134(1):44-54.
    View in: PubMed
    Score: 0.025
  47. Estrada-Quintero T, Uretsky BF, Murali S, Griffith BP, Kormos RL. Neurohormonal activation and exercise function in patients with severe heart failure and patients with left ventricular assist system. A comparative study. Chest. 1995 Jun; 107(6):1499-503.
    View in: PubMed
    Score: 0.021
  48. Sueta CA, Gheorghiade M, Adams KF, Bourge RC, Murali S, Uretsky BF, Pritzker MR, McGoon MD, Butman SM, Grossman SH, et al. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group. Am J Cardiol. 1995 Jan 19; 75(3):34A-43A.
    View in: PubMed
    Score: 0.021
  49. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BR, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow JJ, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Morais J, Aguiar C, Almahmeed W, Arnar DO, Barili F, Bloch KD, Bolger AF, Botker HE, Bozkurt B, Bugiardini R, Cannon C, de Lemos J, Eberli FR, Escobar E, Hlatky M, James S, Kern KB, Moliterno DJ, Mueller C, Neskovic AN, Pieske BM, Schulman SP, Storey RF, Taubert KA, Vranckx P, Wagner DR. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012 Oct 16; 60(16):1581-98.
    View in: PubMed
    Score: 0.018
  50. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasch? P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S. Third universal definition of myocardial infarction. Eur Heart J. 2012 Oct; 33(20):2551-67.
    View in: PubMed
    Score: 0.018
  51. Murali S, Uretsky BF, Armitage JM, Tokarczyk TR, Betschart AR, Kormos RL, Stein KL, Reddy PS, Hardesty RL, Griffith BP. Utility of prostaglandin E1 in the pretransplantation evaluation of heart failure patients with significant pulmonary hypertension. J Heart Lung Transplant. 1992 Jul-Aug; 11(4 Pt 1):716-23.
    View in: PubMed
    Score: 0.017
  52. Murali S, Uretsky BF, Reddy PS, Tokarczyk TR, Betschart AR. Reversibility of pulmonary hypertension in congestive heart failure patients evaluated for cardiac transplantation: comparative effects of various pharmacologic agents. Am Heart J. 1991 Nov; 122(5):1375-81.
    View in: PubMed
    Score: 0.017
  53. Murali S, Uretsky BF, Betschart AR, Tokarczyk TR, Kolesar JA, Reddy PS. Differential hemodynamic effects of oral enoximone in severe congestive heart failure. Am J Cardiol. 1990 Feb 15; 65(7):515-9.
    View in: PubMed
    Score: 0.015
  54. Villanueva FS, Murali S, Uretsky BF, Reddy PS, Griffith BP, Hardesty RL, Kormos RL. Resolution of severe pulmonary hypertension after heterotopic cardiac transplantation. J Am Coll Cardiol. 1989 Nov 01; 14(5):1239-43.
    View in: PubMed
    Score: 0.014
  55. Stone CK, Uretsky BF, Linnemeier TJ, Shah PK, Amin DK, Snapinn SM, Rush JE, Langend?rfer A, Liang CS. Hemodynamic effects of lisinopril after long-term administration in congestive heart failure. Am J Cardiol. 1989 Mar 01; 63(9):567-70.
    View in: PubMed
    Score: 0.014
  56. Murali S, Uretsky BF, Kolesar JA, Valdes AM, Reddy PS. The acute effect of an oral "inotropic" placebo on the exercise capacity of patients with chronic cardiac failure. Chest. 1988 Aug; 94(2):262-6.
    View in: PubMed
    Score: 0.013
  57. Murali S, Uretsky BF, Valdes AM, Kolesar JA, Reddy PS. Acute hemodynamic and hormonal effects of CI-930, a new phosphodiesterase inhibitor, in severe congestive heart failure. Am J Cardiol. 1987 Jun 01; 59(15):1356-60.
    View in: PubMed
    Score: 0.012
  58. Rangasetty UC, Raza S, Lick S, Uretsky BF, Birnbaum Y. Chronic pseudoaneurysm and coarctation of the aorta: a rare delayed complication of trauma. Tex Heart Inst J. 2006; 33(3):368-70.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.